Pharmaceutical Technology
MAY 26, 2023
These figures are only expected to grow in the coming years, with sales forecasted to reach over $150 billion by 2028. Checkpoint modulators and cell therapies lead the way in the pre-registration stage, which features no cancer vaccines and oncolytic virus-focused therapies, she added.
European Pharmaceutical Review
FEBRUARY 8, 2023
It is set to retain its market-leading position as the most lucrative CD19 CAR-T agent in NHL, with annual sales reaching $1.7 Breyanzi is approved for DLBCL, and a label expansion is anticipated for expansions into marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL) in 2026 and 2028, respectively.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PM360
SEPTEMBER 21, 2023
CMS negotiation may lead to additional savings for beneficiaries and for the Medicare program. After this period, CMS will begin to include physician-administered drugs covered under Part B in the program. The IRA sets physician reimbursement of these products at the CMS-established MFP plus 6% versus current average sales price.
Clarivate
OCTOBER 25, 2023
The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. Part D cannot cover drugs covered under Part A or Part B , forcing them to be addressed separately.
Clarivate
APRIL 18, 2024
In 2023, Humana’s care delivery component CenterWell launched a senior-centered “ Primary Care Anywhere ” program for in-home primary care in Georgia and Louisiana (where Humana leads the MA sectors) and increased senior membership in value-based home care models nationwide to more than 840,000.
Nixon Gwilt Law
MAY 26, 2023
CMS and other payors do not currently pay for these codes , but billing practitioners should continue to submit claims including the codes to provide necessary information that will hopefully lead to more reimbursement opportunities for VR in the future. Telehealth. Remote Therapeutic Monitoring (“RTM”).
PM360
APRIL 7, 2023
However, Medicare will only be able to negotiate prices for 10 Part D drugs in 2026, another 15 Part D drugs in 2027, another 15 Part D and Part B drugs in 2028, and another 20 Part D and Part B drugs for 2029 and subsequent years. It’s amazing we still separate the drug costs from overall healthcare costs,” Sontupe says.
Expert insights. Personalized for you.
105 
Let's personalize your content